Press Releases

Richter and Mithra strengthen their partnership and signed a license and supply agreement for the commercialization of Estelle® to Latin America
23 December 2020
EN FR

Mithra Announces Positive DSMB Safety Review and Continuation of its Phase III Clinical Program Donesta® in menopause
16 December 2020
EN FR

Mithra announces final terms of its offering of EUR 125 million convertible bonds due 2025
10 December 2020
EN FR

Mithra announces placement of EUR 125 million convertible bonds due 2025
10 December 2020
EN FR

Mithra launches an offering of up to EUR 150 million convertible bonds due 2025
10 December 2020
EN FR

Scientific community convinced of Estetrol’s potential for women’s health
3 December 2020
EN FR

Mithra’s exclusivity on Estetrol applications extended to 2036 in Europe
30 November 2020
EN FR

Estetrol recognized as a “New Active Substance” by the European Medicines Agency (EMA)
25 November 2020
EN FR

Creation of a New Share Option Plan in Replacement of the 2018 Share Option Plan
20 November 2020
EN FR

E4/DRSP, a Novel Combined Oral Contraceptive, submitted to Brazilian regulatory authorities
17 November 2020
EN FR

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Venezuela
10 November 2020
EN FR

Mithra Renews its Board of Directors to Support its Operational Ambitions
3 November 2020
EN FR

Mithra Signs LSA for Commercialization of Estelle® in North Africa
19 October 2020
EN FR

Mithra Announces FDA update
6 October 2020
EN FR

Mithra Announces 2020 Half Year Results
24 September 2020
EN FR

Interim Financial Report as at 30 June 2020
24 September 2020
EN FR

Mithra to Host Webcast for Half Year Financial Results on 24 September 2020
21 September 2020
EN FR

Mithra’s EGM Approves Warrant Plan for Share Lending Shareholders
7 September 2020
EN FR

Publication of a Transparency Notification Received from Alychlo NV
20 August 2020
EN FR

Mithra Announces Commercial Launch of Myring™ in the Netherlands
19 August 2020
EN FR

Notice of Extraordinary Shareholders’ Meeting on 7th September 2020 Regarding Proposed Warrant Plans
7 August 2020
EN FR

Information on the Total Number of Voting Rights (Denominator) Following the Completion of the LDA Capital Increase
5 August 2020
EN FR

Mithra announces shelf life extension for Myring™ to 36 months
4 August 2020
EN FR

Mithra Announces Commercial Launch of Tibelia® in Canada
30 July 2020
EN FR

Mithra’s EGM Approves Warrant Plan for LDA Capital
23 July 2020
EN FR

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Mexico
14 July 2020
EN FR

Publication of a Transparency Notification Received from Alychlo NV
10 July 2020
EN FR

Publication of a Transparency Notification Received from Ogesip Invest SA
9 July 2020
EN FR

Mithra Signs LSA for Commercialization of Myring™ in France, Poland and United Kingdom
6 July 2020
EN FR

Mithra Announces FDA Filing Acceptance of New Drug Application for Estelle® in the US
24 June 2020
EN FR

Information on the Total Number of Voting Rights (Denominator)
23 June 2020
EN FR

Notice of Extraordinary Shareholders’ Meeting on 22th July 2020 Regarding Proposed Warrant Plans
19 June 2020
EN FR

Mithra Successfully Raises EUR 65 Million By Means of a Private Placement via an Accelerated Bookbuild Offering
18 June 2020
EN FR

Mithra Launches Capital Increase By Means of a Private Placement via an Accelerated Bookbuild Offering and Provides an Update on its Financing Strategy
18 June 2020
EN FR

Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland
11 June 2020
EN FR

Mithra Issues First Put Option Notice Under Capital Agreement with LDA Capital
5 June 2020
EN FR

Mithra Signs License and Supply Agreement with Mayne Pharma for Commercialization of Estelle in Australia
28 May 2020
EN FR

Mithra Launches a Research Programme on Estetrol’s Effect in Covid-19 Treatment
25 May 2020
EN FR

Mithra and Searchlight Pharma Announce Filing of New Drug Submission for Estelle® in Canada
20 May 2020
EN FR

Mithra and Gynial Sign Commercialization Agreement for Myring™ in Switzerland
5 May 2020
EN FR

Mithra Obtains a Capital Commitment Agreement of EUR 50 Million from Partner LDA Capital
24 April 2020
EN FR

Mithra Releases 2019 Annual Report and Invitation to its Securities holders’ Meeting
22 April 2020
EN FR

Mayne Pharma Submits New Drug Application For E4/DRSP to the FDA
16 April 2020
EN FR

Mithra Announces Commercial Launch of Myring™ in Germany, the biggest market in Europe
2 April 2020
EN FR

Mithra Announces Donesta® Phase III Clinical Program Update
1 April 2020
EN FR

Mithra Reports Full Year 2019 Financial Results
9 March 2020
EN FR

Mithra to Host Webcast for Announcement 2019 Financial Results on 9 March 2020
5 March 2020
EN FR

Mithra Receives acceptance of Marketing Authorization Application (MAA) to market Estelle® in Belgium and Luxembourg
3 March 2020
EN FR

EMA Accepts Richter’s Marketing Authorization Application (MAA) for Estelle®, a Novel Combined Oral Contraceptive
27 February 2020
EN FR

Mithra Announces Commercial Launch of Myring™ in Belgium
12 February 2020
EN FR

Mithra receives positive ruling on Patent Income Deduction
10 February 2020
EN FR

Reaction of the CEO and the Board of Directors of Mithra following the articles published in the Belgian press
23 January 2020
EN FR

Mithra Signs LSA for Commercialization of Myring™ in Italy, the Third Biggest Worldwide Market
21 January 2020
EN FR

Mithra Announces 2020 Financial Calendar
15 January 2020
EN FR

E4 Paves the Road Towards a Revolutionary Era of Environmental Friendly Medicines
10 January 2020
EN FR

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Italy
7 January 2020
EN FR

Mithra Signs LSA with Alvogen for Commercialization of Estelle® in Hong Kong and Taiwan
6 January 2020
EN FR